MicroRNAs are short noncoding RNAs that function as negative regulators of gene expression. Posttranscriptional regulation by miRNAs is important for many aspects of development, homeostasis, and disease. Endothelial cells are key regulators of different aspects of vascular biology, including the formation of new blood vessels (angiogenesis). Here, we review the approaches and current experimental evidence for the involvement of miRNAs in the regulation of the angiogenic process and their potential therapeutic applications for vascular diseases associated with abnormal angiogenesis. (Circ Res. 2009;104:442-454.)
A ll blood vessels are lined by the vascular endothelium, a critical barrier between the circulating blood and tissue. The nonthrombogenic surface of the endothelium permits the flow of blood to meet the metabolic demands of tissues and alterations in flow patterns are determined by the changes in pressure and vascular resistance in a given vascular segment. 1 The de novo generation and remodeling of blood vessels is essential to embryonic growth and throughout postnatal life. With regard to the latter, dynamic regulation of vascular density is critical for physiological organ repair during wound healing, postischemic tissue restoration, and the menstrual cycle. During adulthood, the endothelium remains essentially quiescent, to fulfill its main function to conduct nutritive blood flow to organs, with turnover rates on the orders of months to years, and rapid changes in endothelial proliferation rates occur following activation of endothelium by angiogenic cytokines. 2 The loss of typical endothelial quiescence and barrier function is a common feature of conditions such as inflammation, tumor progression, atherosclerosis, restenosis, and various vasculopathies. 3 The formation of the vascular system starts with the assembly of embryonic progenitors cells to form the vascular plexus of small capillaries in a process known as vasculogenesis. This phase is followed by angiogenesis resulting in the expansion of the nascent vascular plexus by sprouting and remodeling into a highly organized and stereotypic network of larger arterial and venous vessels ramifying into smaller ones. 3, 4 Therefore, vasculogenesis and angiogenesis are physiological processes during development that are downregulated in the healthy adult (except for the organs of the female reproductive system) and are almost exclusively associated with pathology when angiogenesis is induced by microenvironmental factors such as hypoxia or inflammation. 2, 5, 6 The pathological processes associated with or induced by angiogenesis include diseases as diverse as cancer, macular degeneration, psoriasis, diabetic retinopathy, and thrombosis and inflammatory disorders including arthritis and atherosclerosis. Moreover, insufficient angiogenesis is characteristic of ischemic heart disease, peripheral vascular disease, and preeclampsia. 3 The examples above represent the broad array of diseases that are associated with the activated endothelial cell (EC) phenotype.
On angiogenic activation, ECs proliferate, degrade extracellular matrix, change their adhesive properties, migrate, avoid apoptosis, form tube-like structures, and eventually mature into new blood vessels. Therefore, the growth of vessels is a complex process involving a number of molecular and cellular events that require to be temporal and spatial orchestrated by a finely tuned balance between stimulatory and inhibitory signals. 7 Finally, all these processes are controlled by signals received by ECs from their microenvironment, signals whose transduction pathways lead to specific programs of gene expression to ensure an adequate angiogenic response. 8, 9 MicroRNAs (miRNAs) have emerged as crucial players regulating the magnitude of gene expression in a variety of organisms. 10 This class of short (Ϸ22 nucleotides) noncoding RNA molecules have been shown to participate in almost every cellular process investigated so far, 11 and their dysregulation is observed in, and might underlie, different human pathologies including cancer, heart disease, and neurodegeneration. [12] [13] [14] [15] These new molecular regulators have been identified in ECs, and their role in the regulation of different aspects of the angiogenic process has been recently investigated in a variety of laboratories. 16 -22 The present review focuses on the approaches and present experimental evidence for the involvement of miRNAs in the angiogenic process and their potential therapeutic applications for vascular diseases associated with abnormal angiogenesis.
miRNAs: Biogenesis and Modus Operandi
Since the discovery of the first 2 miRNAs, lin-4 and let-7, [23] [24] [25] hundreds of miRNAs have been identified in plants, animals, and viruses by molecular cloning and bioinformatics approaches. 26 miRNAs constitute a family of short noncoding RNA molecules of 20 to 25 nucleotides in length that regulate gene expression at the posttranscriptional level. 27, 28 They generally repress target mRNAs through an antisense mechanism. In animals, miRNAs typically target sequences in the transcript 3Ј untranslated regions (3ЈUTRs) that are only partially complementary to the miRNA, causing a repression of the protein synthesis. 29 They are involved in the control of a wide range of biological functions and processes, such as development, differentiation, metabolism, growth, proliferation, and apoptosis, 11, 12, 14, 27, 28, 30 and are the center of attention in molecular and cell biology research. More than 700 human miRNAs have been cloned and bioinformatic predictions indicate that mammalian miRNAs can regulate approximately 30% of all protein-coding genes. 29, 31 Most miRNAs are transcribed by RNA polymerase II from individual miRNAs genes, from introns of protein coding genes, or from polycistronic transcripts that often encode multiple related miRNAs. 32 These long (thousands of nucleotides) primary transcripts generate a stem-loop containing primary miRNA (pri-miRNA). The pri-miRNA is processed within the nucleus by a ribonuclease III (RNase III), called Drosha, 33 along with an RNA-binding protein, DGCR8/Pasha (Figure 1 ). 34 Most mammalian miRNAs that are encoded in introns are processed before splicing; however, there is a subset of intronic miRNAs called "miRtrons" that circumvent the Drosha pathway. 35 The product of the Drosha cleavage event is a 70-to 100-nucleotide hairpin-shaped precursor (pre-miRNA) that is transported to the cytoplasm via an Exportin-5 and Ran-GTP-dependent mechanism. 36 Then the pre-miRNA is further cleaved to produce the mature Ϸ22-nt miRNA:miRNA* duplex by another RNaseIII enzyme, Dicer (Figure 1 ). 37 The miRNA duplex is incorporated into the effector ribonucleoprotein complex RISC (RNA-induced silencing complex), 38, 39 whose key components are proteins of the Argonaute family ( Figure 1 ). 40 The miRNA duplex is unwound into the mature single-stranded form (guide strand) and its complementary strand (passenger strand or miRNA*) that is typically degraded. The stem loop in pre-miRNAs contributes to the strand selection; however, the miRNA* also has a chance to be selected and used in gene regulation. 41 As part of the RISC, the miRNA guides the complex to its RNA targets by Watson-Crick base-pairing interactions. In cases of perfect or near-perfect complementary to the miRNA, target mRNA 3ЈUTRs can be cleaved and degraded. In most cases, animal miRNAs pair imperfectly with their targets and their translation is repressed. 42 The mechanism(s) of translational repression by miRNAs remains unclear and can also affect mRNA stability. These include sequestration from ribosomes (by relocation into P bodies), blockage of translational initiation, translational repression after initiation, and target deadenylation coupled to transcript degradation ( Figure 1 ). 42, 43 Recent reviews covering these topics and more general information about biogenesis and mechanisms of action can be found. 11, 12, 29, 44 Elucidation of the function of a miRNA requires identification of putative mRNA targets that it regulates, and this is very challenging because miRNA usually are imperfectly complementary to their targets. In mammals, the most consistent requirement, although not always essential, of miR-NA:target interaction is a contiguous and perfect base pairing of the miRNA nucleotides 2 to 8, representing the "seed" region. In many cases, the seed seems to determine this recognition; in other cases, additional determinants are required, such as reasonable complementarity to the miRNA 3Ј half to stabilize the interaction, mismatches must to be present in the central region of the miRNA-mRNA, among others. 12, 29, 45, 46 It is important to note that identifying functionally important miRNAs targets is crucial for understanding miRNA functions. However, the possibility that a single miRNA may target multiple transcripts within a cell type and that individual transcripts may be subject to regulation by multiple miRNAs amplifies the scope of putative miRNA regulation of gene expression and indicates that the particular cellular context of a given miRNA will determine its function in a specific cell type.
Regulation of Angiogenesis by miRNAs: Global Approaches
An approach to examine the spectrum of the biological significance of miRNAs is to remove all miRNAs by mutation or disruption of Dicer, the rate-limiting enzyme involved in the maturation of miRNAs. Dicer loss of function results in profound developmental defects in both zebrafish and mice. 47, 48 Zebrafish lacking Dicer undergo to a relative normal morphogenesis and organ development but die 2 weeks after fertilization because of a general growth arrest. 48 The survival to this stage likely reflects the presence of maternal Dicer. When an offspring of fish that lack both maternal and zygotic Dicer was created, 49 these Dicer-null embryos exhibited severe defects most prominently in gastrulation, brain morphogenesis, and cardiac development associated with a disrupted blood circulation. Reminiscent of the zebrafish Dicer-null phenotype, loss of Dicer in mice by replacement of exon 21 with a neomycin-resistance cassette leads to lethality early in embryogenesis, at embryonic day 7.5, and the embryos were depleted of pluripotent stem cells. 47 Another group generated Dicer ex1/2 mice have a deletion of the amino acid sequences from the first 2 exons of the Dicer gene. 50 Dicer ex1/2 homozygous embryos die between days 12.5 and 14.5 of gestation, again demonstrating that Dicer is necessary for normal mouse development. To further explore the consequences of Dicer deletion, several laboratories have generated mice harboring conditional Dicer alleles. Tissue-specific inactivation of Dicer has led to the conclusion that Dicer is essential for proper limb formation, lung and skin morphogenesis, the maintenance of hair follicles, T-cell development, differentiation and function, neuronal survival, skeletal muscle development, chondrocyte proliferation and differentiation, germ cell development and spermatogenesis, autoimmunity and antibody diversity, and B-lymphocytic lineage survival. [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] At the level of the cardiovascular system, cardiac-specific deletion of Dicer produces dilated cardiomyopathy associated with heart fail-ure in neonates 65 and spontaneous cardiac remodeling when Dicer deletion was induced postnatally in the myocardium. 66 Recent reports, both in vitro and in vivo, also indicate a role for Dicer-dependent miRNAs in vascular signaling and functions related to angiogenesis. 16, 19, 20, 50, 67 In fact, the early embryonic lethality observed in Dicer ex1/2 mice has been suggested to be a consequence of defective blood vessel formation and maintenance, 50 data that were in accordance with the disrupted blood circulation observed in zebrafish Dicer-null embryos. 49 The defects observed in Dicer ex1/2 embryos and yolk sacs were associated with altered expression of vascular endothelial growth facto (VEGF), its receptors KDR (VEGFR2) and FLT-1 (VEGFR1), as well as the putative angiopoietin-2 receptor Tie-1. This study suggests that Dicer has a role in embryonic angiogenesis, probably through processing of miRNAs that regulate expression levels of key angiogenic regulators. 50 These observations give rise for a series of studies relating to miRNA and endothelial cells functions relevant to angiogenesis.
The functional role of miRNAs in endothelial cells was assessed by specifically silencing Dicer using short interfering (si)RNA in human umbilical endothelial cells (HUVECs) Figure 1 . miRNA biogenesis and function. miRNAs originate in the nucleus as RNA polymerase II primary transcripts (pri-miRNAs), which are transcribed from independent miRNA genes, from polycistronic transcripts, or from introns of protein-coding genes. Pri-miRNAs are then processed in 2 steps, catalyzed by the RNase III type endonuclease Drosha and Dicer. These enzymes function in complexes with double-stranded RNAbinding domain proteins DGCR8 and TRBP for Drosha and Dicer, respectively. Drosha-DGCR8 processes pri-miRNAs to Ϸ70-nucleotide hairpins known as pre-miRNAs. A subset of miRNAs, called miRtrons, also derived from introns, is processed into pre-miRNAs by the spliceosome and the debranching enzyme. Both canonical miRNAs and miRtrons are exported to the cytoplasm via Exportin 5, where they are further processed by Dicer-TRBP to yield Ϸ20-bp miRNA duplexes. One strand is selected to function as mature miRNA and loaded into the RISC, whereas the partner miRNA* strand is preferentially degraded. The mature miRNA leads to translational repression or mRNA degradation. The key components of the RISC are components of the Argonaute family (Ago1 to -4). A fraction of miRNA* species can also access Ago complex and regulate targets. Perfect complementarity between miRNA and mRNA leads to an endonucleolytic cleavage, catalyzed by the human Ago2 in the RISC. This mechanism applies to siRNAs and many plant miRNAs. Animal miRNAs usually show only partial complementarity to the target mRNA promoting translational repression (initiation and post initiation steps) or deadenylation coupled to exonucleolytic degradation of target mRNA. mRNAs repressed by deadenylation or at the translation-initiation step are moved to P-bodies for either degradation or storage. and EA.hy.926 cells. Depletion of Dicer impairs the development of capillary-like structures and exerts an antiproliferative effect. 16, 19, 20 The knockdown of Dicer in human microvascular endothelial cell (HMECs) shows diminished tube formation and cell migration. 67 Accordingly, migration was also impaired in Dicer knockdown HUVECs when fibronectin was used as matrix. 16 As expected, the knockdown of Dicer in ECs alters constitutive protein expression patterns, largely affecting proteins that play a role in endothelial cell biology and angiogenic responses, such us Tie-2/ TEK, VEGFR2, endothelial nitric oxide synthase (eNOS), interleukin-8, and angiopoietin-like 4 (ANGPTL4). 19 Some of the upregulated transcripts/protein were consistent with the reported Dicer ex1/2 embryos, such as of Tie-2/TEK and VEGFR2. 19, 50 The decrease in growth and morphogenesis observed in ECs after Dicer silencing 16, 19, 20 was consistent impaired vascular development in Dicer ex1/2 embryos and regardless of the paradoxical upregulation of VEGFR1 and VEGFR2 observed in Dicer ex1/2 embryos 50 and VEGFR1, VEGFR2, Tie-2, and eNOS observed in Dicer-knockdown ECs. 19 Interestingly, the Dicer silencing in ECs increased the expression of thrombospondin-1 (Tsp1), 16, 20 a multidomain matrix glycoprotein that has been shown to be a natural endogenous inhibitor of angiogenesis, which may explain, in part, the antiangiogenic phenotypes observed in vitro. Furthermore, the knockdown of Dicer in HMECs also reduces the expression of miRNAs that control the expression of the HMG-box protein 1 (HBP1) transcriptional suppressor, which negatively regulates p47phox of the NADPH oxidase complex and decreases the basal production of reactive oxygen species, impairing aspects of redox regulation during an angiogenic response. 67 The early embryonic lethality of Dicer-null alleles in mice 47, 50 has limited the ability to address the role of Dicer in normal mouse growth and development. The global effect of Dicer deficiency in adult mice was investigated by using a Dicer hypomorphic mouse (Dicer d/d ), obtained by a gene-trap method. 68 Dicer d/d female mice are infertile because of corpus luteum (CL) insufficiency and defective ovarian angiogenesis. CL is formed from the ovulated follicle and plays a critical role in the secretion of progesterone, a hormone needed for the maintenance of early pregnancy, and requires intense angiogenesis. Impaired CL angiogenesis was partly explained by the lack of miR-17-5p and let7b, miRNAs that participate in angiogenesis via targeting the antiangiogenic factor TIMP1 (tissue inhibitor of metalloproteinase 1). 69 Although CL angiogenesis was reduced, embryonic vasculogenesis and angiogenesis were not affected in Dicer d/d mice, indicating that angiogenesis in different tissues has different sensitivities to the levels of Dicer protein. 68, 69 The first attempt to show the role of endothelial miRNAs in angiogenesis in vivo was performed by subcutaneous injection of Dicer knockdown in HUVECs (suspended in a Matrigel plug) into nude mice, demonstrating reduced sprout formation. 16 Finally, the requirement of endothelial miRNAs for postnatal angiogenesis was recently tested by the generation of 2 EC-specific Dicer knockout mouse lines, conditional Tie2-Cre;Dicer flox/flox mice and the tamoxifeninducible VECad-Cre-ER T2 ;Dicer flox/flox mice. 20 Despite the fact that Dicer protein was reduced and miRNA production diminished (eg, miR-126 and miR-31) in ECs isolated from Tie2-Cre;Dicer flox/flox mice, they were viable and overtly normal, suggesting the mice were hypomorphic for Dicer expression in the endothelium. However, the lack of lethality allowed investigation of the relevance of endothelial miRNAs in postnatal angiogenic responses using several models of angiogenesis. VEGF (VEGF-A) is a major proangiogenic factor whose main functions are to promote EC survival, induce EC proliferation, and enhance cell migration and invasion of ECs, all phenotypes that promote angiogenesis. As shown previously in human ECs transfected with Dicer siRNA, 16, 19 VEGF-driven angiogenesis is reduced in mice that are conditional EC-specific Dicer hypomorphs. 20 Altered miRNA expression has been implicated in tumor formation via miRNA modulation of critical genes involved in tumor cells proliferation or survival. 14, 70 Importantly, angiogenesis is necessary for adequate delivery of nutrients and oxygen to growing tumors. 71 Interestingly, the participation of endothelial miRNAs in the tumor-induced neovascularization was examined by postnatal inactivation of Dicer in the endothelium before tumor implantation. Tumor growth as well as the tumor-induced microvessel formation was reduced in VECad-Cre-ERT2;Dicer flox/flox . 20 Taken together, miRNAs participate and are required for tumor cell proliferation plus angiogenesis. The pathophysiological relevance of endothelial miRNAs was also further investigated in response to limb ischemia and wound healing. 20 The vascular supply to limbs and peripheral tissues is essential for normal physiological functions. Under certain pathological conditions, however, vascular supply may be reduced to such an extent that it leads to necrosis of the tissue. After ischemia, inactivation of Dicer in ECs reduced the angiogenic response to limb ischemia indicated by a reduction in capillary densities and blood flow recovery. The reduced flow impaired lower limb function and resulted in higher ischemic damage scores. 20 Recent studies on the significance of miRNA in skin morphogenesis and development provide important insight that lay the foundation for the wound-healing process 53, 54 ; the potential significance of miRNAs in cutaneous wound angiogenesis has also been discussed. 72 As mentioned above, angiogenesis is necessary for wound repair because the new vessels provide nutrients to support the active cells, promote granulation tissue formation, and facilitate the clearance of debris. Cutaneous wound healing was delayed when Dicer was inactivated in ECs. Tie2-Cre;Dicer flox/flox and, postnatally, VECad-Cre-ERT2;Dicer flox/flox show larger areas of granulation tissue devoid of hair follicles, with less granulation tissue deposition and collagen accumulation, 20 hallmarks of an angiogenic response.
The knockdown of Drosha, which is involved in the processing of pri-miRNAs, was also undertaken to globally reduce miRNAs. The silencing of Drosha in ECs produces less pronounced effects on angiogenesis than Dicer silencing, 16, 19 although capillary sprouting and tube forming activity were blunted; the knockdown of Drosha does not exert significant effects on the in vivo Matrigel plug model. 16 This may be explained by the processing of pri-miRNA independent of Drosha. 35 On the other hand, the angiogenic potential of ECs disappeared when Ago2, a component of the RISC, was knockdown. 73 Of the 4 mammalian Argonautes (Ago1 to -4), only Ago2 functions in the RNA interference pathway, 74, 75 whereas all 4 seem to participate in the miRNAmediated repression, indicating that the global impairment of repression by impeding miRNA-mRNA interaction also affect EC angiogenic responses.
These experimental approaches likely reveal the consequences of a block in miRNA biogenesis; however, when interpreting the data, it is important to consider the fact that Dicer may participate in other processes unrelated to miRNA biology, such as formation of the heterochromatin, 76 and that there are alternative Drosha-independent pri-miRNA processing pathways. 35 Deciphering the miRNA network responsible for the modulation of the angiogenesis might lead to novel therapeutic approaches for cancer, wound healing, and ischemic conditions such myocardial ischemia, peripheral vascular disease, and vascular diabetic complications.
Role of Individual miRNA in Angiogenesis
Although the previous studies emphasize the importance of the miRNA pathway in several aspects of the angiogenic process, the majority does not provide information regarding the functions of specific miRNAs. Studies aimed at elucidating the role of individual miRNAs in the regulation of angiogenesis are increasingly being performed and most of the examples that illustrate principles of miRNA function in angiogenesis are presented here.
Many miRNAs exhibit striking organ-specific expression patterns suggesting cell type-specific functions. [77] [78] [79] Consequently, dysregulation of miRNA expression and function may lead to human diseases. 12 The first large-scale analysis of miRNA expression in ECs was carried out in HUVECs and identified 15 highly expressed miRNAs with receptors of angiogenic factors (Flt-1, Nrp-2, Fgf-R, c-Met, and c-kit) as putative mRNA targets, according to prediction algorithms. 18 Additional studies also profiled the expression of miRNAs in ECs. 16, 19 The highly expressed miRNAs that were common in at least 2 of the 3 studies, included miR-15b, -16, -20, -21, -23a and -b, -24, -29a and -b, -31, -99a, -100, -103, -106, 125a and -b, -126, -130a, -181a, -191, -221, -222, -320, let-7, let-7b, let-7c, and let-7 days. 16, 18, 19 However, their specific targets and functions in ECs related to angiogenesis have only been characterized for a few of them (Table) .
The prediction algorithms used to find receptors for angiogenic factors that may potentially be targeted by some of the miRNAs identified miR-221 and miR-222 to target c-kit. 18 c-kit is a tyrosine kinase receptor for stem cell factor and has been shown to promote survival, migration, and capillary tube formation in HUVECs. 80 Interestingly, transfection of HUVECs with miR-221/222 inhibits tube formation, migration, and wound healing in response to stem cell factor. 18 miR221/222 were shown to control the growth of erythropoietic and erythroleukemic cells, through the regulation of c-kit expression at the translational level. 81 Accumulating evidence suggests that bone marrow-derived circulating precursors contribute to vascular repair, remodeling, and lesion formation under physiological and pathological conditions. 82 Interestingly, the interaction between miR-221/222 and the c-kit 3ЈUTRs was also demonstrated in ECs and thus the antiangiogenic activity of these miRNAs. 18 miR221/222 overexpression in Dicer-knockdown ECs restored the elevated eNOS protein levels eNOS induced by after Dicer silencing. 19 NO synthesized by eNOS is necessary for EC survival migration and angiogenesis. 83 However, prediction sites for these miRNA were not found in eNOS 3ЈUTR, suggesting that the regulation of eNOS protein levels by miR-221/222 is likely to be indirect. Collectively, these reports suggest an antiangiogenic action for these miRNAs and then might be a potential tool to block angiogenesis. However, it is important to note that miR221/222 can also promote cancer cell proliferation through the regulation of p27(Kip1) tumor suppressor, 84 indicating that the regulation of proliferation by these miRNAs appears cell type specific. Therefore, cellspecific targeting with miRNAs is an important area of investigation to be developed.
Other miRNAs expressed in ECs, let-7f and miR-27b, have been shown to exert proangiogenic effects, as revealed by the blockade of in vitro angiogenesis with 2Ј-O-methyl oligonucleotides inhibitors, 16 although their targets in ECs have not been already characterized.
The best-characterized EC-specific miRNA is miR-126. 17,22,85 miR-126 is a highly conserved miRNA (http:// microrna.sanger.ac.uk/sequences/index.shtml). In both mouse and zebrafish, miR-126 is enriched in tissues with a high vascular component such as the lung and the heart. 86, 87 In mammals, it is encoded by intron 7 of the EGF-like domain 7 (Egfl7) gene also known as VE-statin, which encodes an EC-specific secreted peptide that acts as a chemoattractant and inhibitor of smooth muscle cell migration. 88, 89 Location of miRNAs within noncoding regions of specific genes represents a common mechanism of coregulation. Although the intronic miRNAs and their host genes could be regulated independently, it is possible that the signals that activate the transcription of the host gene lead to the transcription of the intronic miRNA. These miRNAs can in turn mediate the regulation of its host protein-coding gene or the regulation of other proteins whose expression is inappropriate for the stimulated process. In this regard, miR-208, is a cardiacspecific miRNA encoded by an intron in the gene that encodes ␣-myosin heavy chain and functions within a regulatory network to control cardiac stress response. 79 Thus, the expression pattern of miR-126 in tissues and cells lines 22 parallels that of Egfl7. 90, 91 Additionally, miR-126 has been shown to be enriched in embryonic body-derived Flk1positive cells. Indeed, the expression of Egfl7 and miR-126 largely matched that of EC markers during embryoid body formation, being highly enriched in Flk1-positive vascular progenitors at embryonic day 4, as well as in mature CD31expressing ECs at embryonic day 7. 17 Although enriched in vascular progenitors, it is not sufficient to promote the differentiation of pluripotent cells toward an EC lineage. 17 In vitro, miR-126 regulates many aspects of EC biology, including cell migration, organization of the cytoskeleton, capillary network stability, and cell survival. 17 In vivo, the knockdown of miR-126 in zebrafish resulted in the loss of vascular integrity and hemorrhage during embryonic development. 17 Furthermore, targeted deletion of miR-126 in mice causes 22 In fact, PECAM staining revealed extensive vascularization in the injured myocardium of wild-type mice, whereas there it was reduced in miR-126 Ϫ/Ϫ mice. 22 Vascular cell adhesion molecule (VCAM)-1 was the first target identified for repression by miR-126 in vitro, 85 however additional targets have been identified. 17, 22 Gene expression profiles by microarray analysis of ECs isolated from adult kidneys of wild-type and miR-126 Ϫ/Ϫ mice 22 or from miR-126 zebrafish morphants or from HUVECs in which miR-126 was knockdown 17 were performed to identify genes regulated by miR-126. Genes implicated in endothelial cell biology, angiogenesis, cell cycle, inflammation, cytoskeleton, and growth factors were dysregulated in the absence of miR-126. 17, 22 Bioinformatic analysis, predicted integrin ␣-6, VCAM-1, and Sprouty-related protein-1 (Spred-1), 17, 22 as well as phosphoinositide 3-kinase, regulatory subunit 2 (PIK3R2), also known as p85-␤, RGS3 (regulator of G protein signaling 3), and CRK. 17 miR-126 directly targets the 3ЈUTRs of Spred-1, 17,22 VCAM-1, 17, 85 and PIK3R2 17 for repression. Spred-1 and PIK3R2 have been shown to function as negative regulators of VEGF/fibroblast growth factor (FGF) signaling via mitogen-activated protein kinase and phosphoinositide 3-kinase pathways, respectively. Thus, miR-126 promotes growth factor (VEGF/FGF) signaling, angiogenesis, and vascular integrity by inhibiting endogenous repressors of growth factors within ECs. 17, 22 These findings illustrate that a single miRNA can regulate vascular integrity and angiogenesis, providing a new target for either pro-or antiangiogenic therapies. As mentioned above, numerous factors are implicated in vessel growth. Among these factors, angiotensin (Ang) II, the main effector peptide of the renin-angiotensin system, appears to be implicated in the regulation of the angiogenic process. 92 Ang II has been shown to work through both type 1 (AT 1 R) and type 2 (AT 2 R) receptors, which display opposing vasomotor and angiogenic actions. 93 AT 1 R activation is known to stimulate vascular growth and microvascular angiogenesis in nonneural tissues such as skeletal and cardiac muscle, whereas AT 2 R activation was recently shown to antagonize these actions. 94 miR-155 is expressed in ECs and VSMCs 20,95 and has been shown to specifically interact with the 3ЈUTRs of the human AT 1 R mRNA, thereby reducing the endogenous expression of the hAT 1 R and consequently Ang II signaling. 95 Translational repression by miR-155 provides yet another mechanism by which AT 1 R expression can be modulated. In this regard, it has been reported that Ang II induces the expression of VEGFR2 in a dose-dependent manner and significantly enhances VEGF-induced cell proliferation and tube formation, mediated by AT 1 R, 96 suggesting that AT 1 R may contribute to the development of diabetic retinopathy by enhancing VEGF-induced angiogenic activity. Then, the downregulation of AT1R by miR-155 suggest an antiangiogenic function for this miRNA in ECs. However, its role in EC angiogenesis has not been specifically addressed. Stimulation of human fibroblast with transforming growth factor (TGF)-␤1 decreased the expression of miR-155 and increased the expression of hAT1R. Furthermore, miR-155 is induced in macrophages by cytokines such as tumor necrosis factor ␣ and interferon-␤. 97 Interestingly, angiogenic stimulation of ECs with VEGF increases the expression of miR-155 20 suggesting VEGF may control the levels of ATR1 via miR-155. Nevertheless, the oncogenic potential of miR-155 has been confirmed in mice, where its overproduction leads to spontaneous B-cell malignancy, showing the complexity of miRNA-mediated regulation, given that the same miRNA may have opposite effects in different biological contexts.
Regulation of miRNA Expression in Angiogenesis
It is well accepted that miRNAs post-transcriptionally govern the levels of gene expression. However an important burgeoning area of investigation is to elucidate how the levels of miRNAs, per se, are regulated. The information about specific regulation of miRNAs has comparatively lagged behind, in contrast to the wealth of publications about their biological effects. Indeed, extracellular factors can modify the activity of a miRNA by affecting its expression, stability (by controlling synthesis or degradation or cellular localization. 98 -102 In this regard, promoter elements that could contribute to the expression of the muscle-specific miR-1/miR-133 cluster have been identified 103 as well as the implicated in miR-223 during granulopoiesis. 98 The oncogenic transcription factor c-Myc activates the miR-17-92 cluster, and this mechanism plays an important role in tumor formation. 101 Furthermore, LPS treatment of human monocytes induced the expression of miR-146, -142, and -155 as determined by miRNA microarrays and that miR-146 was induced in an nuclear factor Bdependent manner. 97, 104 These exciting studies raise the possibility that extracellular signals via Toll-like receptors modulate the expression of key miRNAs which then regulated the levels of genes necessary for Toll-like receptor-dependent functions. This concept of miRNA regulation has been extended to the cytokine interferon-␤, which induces key miRNAs that aid in combating viral infections. 105 More recently, miRNA profiling of TGF-␤ or bone morphogenetic protein-treated human vascular smooth muscle cells revealed that TGF-␤/bone morphogenetic protein induces the expression of miR-21, leading to an upregulation of genes necessary for the contractile phenotype. The mechanism of miR-21 induction is quite novel, where TGF-␤ enhances the processing of pri-miR-21 into pre-miR-21 by regulating the miRNA processing enzyme Drosha. 106 Accordingly, extracellular signals can modify the levels of a miRNA and thereby its activity providing a mechanism to regulate the robustness of an integrated functional response such as an angiogenic response ( Figure 2) . Recent studies investigated the regulation of miRNAs in ECs in response to serum, hypoxia, VEGF, and tumorderived growth factors. 20, [107] [108] [109] miR-130a is expressed at low levels in quiescent HUVECs and is upregulated in response to fetal bovine serum. 107 miR-130a is a regulator of the angiogenic phenotype of ECs through is ability to modulate the expression of the antiangiogenic homeobox proteins GAX (growth arrest homeobox) and HoxA5. miR-130a antagonizes the inhibitory effect of GAX on EC proliferation, migration, and tube formation and the inhibitory effects of HoxA5 on tube formation. 107 The regulation of angiogenesis by hypoxia is an important component of homeostatic mechanisms that link vascular oxygen supply to metabolic demand. 5 Hypoxia occurs during several pathophysiological circumstances (eg, tumor development, chronic ischemia). In cancer cells, a set of hypoxia-regulated miRNAs have been identified, 110 -112 supporting a key role of hypoxia inducible factor (HIF) as a transcription factor for miRNA expression during hypoxia 100 ; however, only a few miRNAs promoters have been identified experimentally. 113, 114 Hypoxia induces the expression of different growth factors including VEGF, an important angiogenic factor. For this gene, a group of candidate regulatory miRNAs has been identified recently and the miRNA regulation of VEGF under hypoxia was investigated in cancer cells. 111 Interestingly, most of the miRNAs that were predicted to target VEGF were found to respond to hypoxia, which could lead to an extra layer of complexity in the angiogenic response. miR-15 and -16 regulate VEGF expression but are downregulated by hypoxia. 111 Interestingly, these miRNAs have been shown to induce apoptosis in leukemic cells by targeting the antiapoptotic protein Bcl-2 115 and to block cell cycle progression 116 and are frequently downregulated in chronic lymphocytic leukemia. 117 With regard to ECs, miR-210 is induced by hypoxia. 108 Overexpression of miR-210 in normoxic ECs stimulates the formation of capillary-like structures and VEGF-driven migration, whereas its blockade inhibits the formation of the capillary-like structures and decreases the migration in response to VEGF. The relevant target for miR-210 in hypoxia was Ephrin (Eph)-A3. Ephrin ligands and their receptors have been shown to play a crucial role in the development of the cardiovascular system. Although the importance of Eph-A2 in the regulation of angiogenesis and VEGF signaling has been reported, little is known yet about the specific role of Eph-A3. However, these data suggest that downregulation of Eph-A3 is necessary for the miR-210 -mediated stimulation of capillary-like formation and EC chemotaxis in response to VEGF and may contribute to modulate the angiogenic response to ischemia.
The modulation of the expression of EC miRNAs by VEGF has been recently investigated. 20 VEGF treatment of HUVECs regulated the levels of several miRNAs, among them hsa-miR-191, -155, -31, -17, -18a, and -20a, whose expression was increased; however, little change was observed in the expression of hsa-miR-126 and -222. 20 The first set of miRNAs are commonly overexpressed in human tumors and have been implicated in the control of tumor growth, survival, and angiogenesis. 118 -122 Transcription factors c-myc and E2F control the expression of the miR-17-92 cluster including miR-17, -18a, and -20 and miR-19a, -19b and -92a. 101, 123, 124 Interestingly, VEGF has been shown promote proliferation of cortical neurons precursors by regulating E2F expression. 125 E2F1, E2F2, and E2F3 are involved in the regulation of apoptosis and cell proliferation. 126 Components of this cluster target the expression of E2F1 and target the expression of E2F1, promoting proliferation by shifting the E2F transcriptional balance away from the proapoptotic E2F1 and toward the proliferative E2F3 transcription network. 101, 124 Because the levels of miR-17, -18a, and -20a in quiescent ECs were very low, VEGF induction of these miRNAs suggest that they may regulate the proliferative actions of VEGF. In fact, overexpression of these miRNAs in Dicer-knockdown ECs rescues the defect in cell proliferation and cord formation, 20 suggesting that VEGF-induced proliferation and morphogenesis are mediated in part by miR-17-92 activation. When components of this cluster are overexpressed in tumors cells (Kras-transformed mouse colonocytes), they specifically target antiangiogenic proteins containing thrombospondin type 1 repeats such as Tsp1, connective tissue growth factor, and SPARC. 120 In particular, miR-18 preferentially suppresses connective tissue growth factor expression, whereas miR-19 targets Tsp1. By using the MiRanda algorithm, both miR-18 and -19 are predicted to target Tsp1 (depending on species). In human ECs, miR-18a preferentially targets Tsp1. 20 When ECs are transfected with the components of the miR-17-92 cluster upregulated by VEGF, miR-18a reduces basal levels of Tsp1 expression. Moreover, increased Tsp1 levels by Dicer silencing 16, 20 are restored to control levels by expression of miR-18a. 20 Collectively, these data indicate that VEGF modulation of miRNAs, specifically components of the miR-17-92 cluster, may participate in the control of angiogenic phenotypes in ECs. Furthermore, miR-17-92 miRNAs suppress the expression of the tumor suppressor PTEN and the proapoptotic protein Bim, contributing to the lymphoproliferative disease of miR-17-92 transgenic mice and contributing to lymphoma development in patients with amplifications of the miR-17-92 region. 127 Moreover, deletion of this locus in mice results in smaller embryos and immediate postnatal death. 128 Finally, a recent report shows that glioma or growth factor mediated the induction of miR-296 in primary human brain microvascular ECs, as well as in primary tumor ECs isolated from brain tumors, compared to normal brain ECs. 109 Furthermore, a growth factor-induced miR-296 contribution to angiogenesis is mediated by targeting hepatocyte growth factor-regulated tyrosine kinase substrate (HGS), thereby reducing HGS-mediated degradation of VEGFR2 and platelet-derived growth factor receptor-␤. 109 The identification of miRNAs as regulators of both ECmediated and tumor-induced angiogenesis and as regulators of survival is relevant for the therapy of cancer, suggesting that antagonism of these key miRNAs may be an attractive strategy.
miRNAs As Potential Therapeutics Targets for Angiogenesis
miRNAs are important players and regulators of both angiogenic processes and responses, thus making them promising targets for potential therapeutics. The fact that miRNAs bind to their target mRNAs by Watson-Crick base pairing indicates that the usage of an oligonucleotide complementary to the miRNA that effectively competes with the mRNA target, ie, "antimiRs," represents an obvious and potential effective way of inactivating pathological miRNAs and thus avoiding downregulation of important targets that promote the stimulation of gene expression. 129 -131 Alternatively, miRNA mimics (double-stranded oligonucleotides designed to simulate the function of endogenous mature miRNAs) may induce target down regulation and thereby diminish gene expression; however, this approach has not been tested in vivo. 132, 133 The use of antimiRs in cultured cells have been successful, however, the key development was chemical modification of miRNA inhibitors for in vivo utility. The large body of research discovered during the development of antisense therapeutics have led to effective strategies for the pharmacological delivery of nucleic acids, facilitating the development of siRNA therapeutics 134 and, now, also miRNA therapeutics. 135 Three different chemical modifications have been carried out to fulfill the inhibition of miRNA function in vivo. One class of antimiRs is conjugated to cholesterol (an-tagomiR) to facilitate cellular uptake. Other classes use oligonucleotides with locked nucleotides acid (LNA-antimiRs) or the 2Ј-O-methoxyethyl phosphorothioate (2Ј-MOE) modification. Antagonism of miR-122 in mouse liver using these 3 classes of antimiRs in 3 independent studies found that miR-122 antagonism led to reduced plasma cholesterol levels. 129 -131 An important caveat to these new therapeutic approaches is the cell/tissue specificity. Furthermore, the regulatory actions mediated by miRNAs are complex because they can act both as positive or negative modulators and bind to hundreds of different targets, and each target may be regulated by several miRNAs. Indeed, the same miRNA can cause the opposite biological effect depending on the context, as exemplified by miR-221/221 (ie, targeting important regulators of proangiogenic endothelial cell function [c-kit, eNOS] but also the tumor suppressor p27 [Kip1]) in cancer cells. 84 Conversely, miR-17-92 cluster components have been shown to participate in EC-mediated angiogenic functions 20 and oncogenic functions, as indicated by their upregulation solid tumors such as colorectal cancer, non-small cell lung cancers. 70 Taken together, antimiRs targeting components of this cluster is a feasible strategy for both antitumor and antiangiogenic therapy. The relative specificity of miR-126 expression in ECs and its requirement for vascular integrity and angiogenesis 17, 22 also suggests that it may be a potential target for efficient antimiR therapy in situations of pathological vascularization, such as retinopathy and cancer. However, overexpression of miR-126 must be carefully considered because there is no direct evidence regarding introduction of miR-126 in nonendothelial cells. This underscores the critical importance of cell/tissue-specific miRNA targeting. Therefore, both the inhibition and the mimicry of a miRNA in tissues other than diseased tissue must be considered. With regard to miRNA therapeutics, there are many efforts to develop a more practical and specific strategy suitable for human therapy. A promising approach for siRNA is to use targeting antibodies that undergo internalization after binding to cellspecific surface receptors. To carry siRNA, antibodies can be decorated on liposomes prepackaged with siRNA or fused to positively charged proteins or peptides that bind nucleic acids via electrostatic interactions. 136 -139 Because miRNA mimics constructs are analogous to siRNA molecules, similar strategies could apply for miRNA mimic cell targeting.
Concluding Remarks
miRNAs are a relatively recent discovery that emerged as important regulators of gene expression, and it appears that miRNAs are implicated in most, if not all, cellular processes and many human diseases. In the present review, we have summarized the role of miRNAs in the regulation of angiogenesis and examined their potential applicability for the treatment of diseases associated with aberrant pathological angiogenesis (cancer or macular degeneration) or defective angiogenesis (myocardial ischemia or peripheral vascular disease). miRNAs constitute a fundamental regulatory network for fine-tuning regulation of gene expression and therefore the maintenance of cellular functions necessary for an adequate angiogenic response. The extensive number of miRNAs and the unprecedented complexity guarantee the discovery of new and unanticipated roles of miRNAs in the control of angiogenesis. Genomics efforts, such as massive parallel miRNA and mRNA expression profiling in angiogenic-associated diseases in combination with loss-or gain-of-functions screens in ECs, in combination with adequate target validation and large-scale proteomics are feasible approaches to help understand the complex miRNA-mediated gene regulatory networks in angiogenesis.
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